NDAORALTABLETPriority Review
Approved
Dec 1997
Lifecycle
LOE Approaching
Competitive Pressure
45/100
Clinical Trials
3
Data completeness
4/8 — Partial
Priority Review
Drug data last refreshed 2h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EVISTA (raloxifene hydrochloride) is an oral small-molecule selective estrogen receptor modulator (SERM) approved in 1997 for osteoporosis prevention and treatment in postmenopausal women. It works by selectively binding to estrogen receptors in bone tissue, promoting bone density while avoiding stimulation of breast and uterine tissue.
$0.001BPart D
LOE ApproachingDeclining
As a mature product approaching loss of exclusivity with minimal Part D spending (2,802 claims in 2023), the brand team is likely small and focused on retention and transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
3-year Study of Menostar Versus Evista to Prevent Osteoporosis in Post-menopausal Women
Started Feb 2004
500 enrolled
Osteopenia
Comparison of Raloxifene Hydrochloride and Placebo in the Treatment of Postmenopausal Women With Osteoporosis
Started Nov 1994
7,705 enrolled
Osteoporosis, Postmenopausal
EVA: Evista Alendronate Comparison
Osteoporosis
Career Relevance
Working on EVISTA in 2024 means joining a mature product team focused on defending market share, managing the transition to generic competition, and potentially developing authorized generic strategies. Career growth will be limited by the product's LOE trajectory, making this role best suited for professionals seeking operational excellence in lifecycle management rather than commercial expansion.
Worked on EVISTA at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.